22 research outputs found
Insights on multiple myeloma treatment strategies
The introduction of new agents and management strategies over the past decade has resulted in a major step change in treatment
outcomes with deepening responses and increased survival for patients with multiple myeloma. In daily clinical practice, healthcare
professionals are now faced with challenges including, optimal treatment sequencing and changing treatment goals. In light of this, a
group of experts met to discuss diagnostic and treatment guidelines, examine current clinical practice, and consider how new clinical
trial data may be integrated into the management of multiple myeloma in the future
Assessment of physical vulnerability and potential losses of buildings due to shallow slides
On the possibility of detecting complex sources of earthquakes from data of the centroid moment tensor catalog
Insights on Multiple Myeloma Treatment Strategies
The introduction of new agents and management strategies over the past decade has resulted in a major step change in treatment outcomes with deepening responses and increased survival for patients with multiple myeloma. In daily clinical practice, healthcare professionals are now faced with challenges including, optimal treatment sequencing and changing treatment goals. In light of this, a group of experts met to discuss diagnostic and treatment guidelines, examine current clinical practice, and consider how new clinical trial data may be integrated into the management of multiple myeloma in the future
Randomized, placeboâcontrolled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
Abstract Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated antiâMM activity in preclinical studies and encouraging earlyâphase clinical activity in combination with bortezomib. A randomized, doubleâblind, placeboâcontrolled phase 3 study was conducted to evaluate addition of perifosine to bortezomibâdexamethasone in MM patients with one to four prior therapies who had relapsed following previous bortezomibâbased therapy. The primary endpoint was progressionâfree survival (PFS). The study was discontinued at planned interim analysis, with 135 patients enrolled. Median PFS was 22.7 weeks (95% confidence interval 16·0â45·4) in the perifosine arm and 39.0 weeks (18.3â50.1) in the placebo arm (hazard ratio 1.269 [0.817â1.969]; P = .287); overall response rates were 20% and 27%, respectively. Conversely, median overall survival (OS) was 141.9 weeks and 83.3 weeks (hazard ratio 0.734 [0.380â1.419]; P = .356). Overall, 61% and 55% of patients in the perifosine and placebo arms reported grade 3/4 adverse events, including thrombocytopenia (26% vs 14%), anemia (7% vs 8%), hyponatremia (6% vs 8%), and pneumonia (9% vs 3%). These findings demonstrate no PFS benefit from the addition of perifosine to bortezomibâdexamethasone in this study of relapsed/refractory MM, but comparable safety and OS
Insights on multiple myeloma treatment strategies
The introduction of new agents and management strategies over the past decade has resulted in a major step change in treatment
outcomes with deepening responses and increased survival for patients with multiple myeloma. In daily clinical practice, healthcare
professionals are now faced with challenges including, optimal treatment sequencing and changing treatment goals. In light of this, a
group of experts met to discuss diagnostic and treatment guidelines, examine current clinical practice, and consider how new clinical
trial data may be integrated into the management of multiple myeloma in the future